Subscribe
2020-04-02
Pavel Kapysh / Shutterstock.com
22 June 2021Big PharmaMuireann Bolger

SCOTUS won’t resuscitate Amarin’s Vascepa patents

Amarin has failed to persuade the US Supreme Court to consider reviving six patents on the heart medicine Vascepa (icosapent ethyl), allowing generic drugmakers Hikma Pharmaceuticals and Dr. Reddy’s Laboratories to roll out copycat products.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Amarin petitions Supreme Court to revive Vascepa patents
18 February 2021   Irish pharmaceutical company Amarin has petitioned the Supreme Court to revive its patents on its heart medication Vascepa.
Americas
SCOTUS asks for SG’s view on enablement in antibody dispute
19 April 2022   The US Supreme Court has asked the Solicitor General to wade in on a case centring on the legal concept of enablement that is the crux of an antibody patent dispute between Amgen and Sanofi.
Americas
Amarin appeals ‘skinny label’ loss
23 November 2022   Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Big Pharma
Amarin petitions Supreme Court to revive Vascepa patents
18 February 2021   Irish pharmaceutical company Amarin has petitioned the Supreme Court to revive its patents on its heart medication Vascepa.
Americas
SCOTUS asks for SG’s view on enablement in antibody dispute
19 April 2022   The US Supreme Court has asked the Solicitor General to wade in on a case centring on the legal concept of enablement that is the crux of an antibody patent dispute between Amgen and Sanofi.
Americas
Amarin appeals ‘skinny label’ loss
23 November 2022   Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.

More on this story

Big Pharma
Amarin petitions Supreme Court to revive Vascepa patents
18 February 2021   Irish pharmaceutical company Amarin has petitioned the Supreme Court to revive its patents on its heart medication Vascepa.
Americas
SCOTUS asks for SG’s view on enablement in antibody dispute
19 April 2022   The US Supreme Court has asked the Solicitor General to wade in on a case centring on the legal concept of enablement that is the crux of an antibody patent dispute between Amgen and Sanofi.
Americas
Amarin appeals ‘skinny label’ loss
23 November 2022   Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility